“3D-printing of tablets and opportunities in the field of personalized medicine” – Presented by Steven Erpelinck, TNO Predictive Health Technologies. 3D printing is a promising technique which has shown to deliver added value within the development of personalized medicine. Currently different 3D printing technologies can be discriminated. Different 3D printing techniques will be presented.
The Fused deposition modeling and ink jet printing technique are currently predominately used for 3D printing of oral dosage forms. Several cased will be presented like 3D printing of different geometries and its effect on drug release, 3D printing of multi API’s with different release profiles to generate a “polypill” addressing special medical needs. 3D printing of drugs offer a lot of opportunities but there are also some challenges to tackle. This is especially the case when using the 3D printing technology with highly potent compounds (HPAPI).
Specific safety issues need to be taking in to account as quality checks on stability of the HPAPI and precision of the dosing. Recently the FDA accepted the first 3D printed oral dosage form. At the moment more than 25% of total drugs worldwide today contain HPAPIs. And it is expected that the annual market growth for HPAPI drugs will be 10% till 2018. Given this growth and the interest in personalized medicine it is expected that more and more HPAPI drugs will be manufactured via 3D printing.
About Steven Erpelinck
Steven Erpelinck was born in The Netherlands in 1966. He studied Biotechnology at the University of Applied Science in Delft. He graduated with a thesis about antibody development and measurement of specific DNA damage in skin via laser scan microscopy. After graduating he started his academic career at the Institute of Applied Radiobiology and Immunology closely working together Oncology hospital DDHK in Rotterdam.
He is a co-author in several publications about measuring genetic abbreviations in Leukemia patients via FISH. From 1996 he changed to more commercial roles within the Life Science industry. After being a Sales Manager with a service provider in molecular biology services for twelve years he started his Pharma career in 2007.
At that time he joined TNO in the role as Sr. Business Developer within the group Predictive Health Technologies. In his business development role he is in charge of the PK portfolio, predicting and measuring bioavailability (BA).
Since the last two years he is extensively involved in the microdosing AMS activities. He is also exploring activities in additive manufacturing like the 3D printing of oral dosage forms.
TNO, the Netherlands Organization for Applied Scientific Research, is an independent Research and Technology Organization (RTO).
TNO has a specific department of Additive Manufacturing, focusing on AM processes, materials and AM equipment manufacturing. TNO is leading the European Manufucture subplatform for Additive Manufacturing (www.AM-platform.com)and initiator of many European Additive Manufacutring roadmaps and research projects. Member of the ISO/TC 261 team on standardisation for Additive Manufacturing.